Securities code: 688767 securities abbreviation: Hangzhou Biotest Biotech Co.Ltd(688767) Announcement No.: 2022-004 Hangzhou Biotest Biotech Co.Ltd(688767)
Stock trading abnormal fluctuation announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Hangzhou Biotest Biotech Co.Ltd(688767) (hereinafter referred to as “the company” or “the company”) shares deviated from the daily closing price by more than 30% in two consecutive trading days on January 13 and January 14, 2022. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange and detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation), it belongs to abnormal fluctuation of stock trading.
Profit adjustment risk accumulated by secondary market trading and continuous rise of the company’s stock price: the company’s stock has increased by more than 30% in the last two consecutive trading days, and the continuous rise of the stock price has accumulated more profit adjustment risk. The company specially reminds investors that the number of circulating shares of the company is 22210796, accounting for 20.82% of the total number of shares after issuance, and the listed circulation is small. On January 14, 2022, the turnover rate of stock trading reached 45.64%, of which natural person investors accounted for a large proportion, which was prone to speculation. On January 15, 2022, the company issued the announcement of Hangzhou Biotest Biotech Co.Ltd(688767) 2021 annual performance pre increase at the same time. The company reminded investors to pay attention to investment risks, avoid following the trend of speculation, make rational decisions and invest prudently.
The competition for COVID-19 products in Europe and Australia is fierce. The company’s New Coronavirus antigen self testing reagent products have many similar products or other testing products in the European and Australian markets. The products will face fierce market competition risks.
Uncertain risk of future performance growth: affected by many factors such as overseas epidemic development and epidemic prevention and control policies, market competition, path selection of international epidemic on technical products, product competitiveness and channel ability of the company, customer recognition and so on, the sales volume and profit contribution of the above covid-19 products are relatively uncertain. Other risks that lead to the uncertainty of the company’s operating performance: affected by the covid-19 vaccination plan and the implementation of covid-19 specific drugs, the company’s product capacity expansion is limited, the company’s operating performance is also unpredictable.
According to the company’s self-examination and verification with the controlling shareholder and actual controller, as of the disclosure date of this announcement, there is no material information that should be disclosed but not disclosed.
1、 Details of abnormal fluctuations in stock trading
The deviation of the closing price increase of the company’s stock trading on January 13 and January 14, 2022 has exceeded 30% in total. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange and the rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation), It belongs to abnormal fluctuation of stock trading price.
2、 Relevant information concerned and verified by the company
(I) production and operation
According to the company’s self inspection, the company’s current production and operation activities are normal, there are no major adjustments to the market environment and industrial policies, there are no significant fluctuations in production costs and sales, and the internal production and operation order is normal. (II) major events
After the company’s self-examination and verification by letter to the controlling shareholder and actual controller of the company: as of the disclosure date of this announcement, except for the information publicly disclosed on the designated media, there are no major matters affecting the abnormal fluctuation of the company’s stock trading price; There is no other major information that should be disclosed but not disclosed by the company, including but not limited to major asset restructuring, issuance of shares, acquisition of listed companies, debt restructuring, business restructuring, asset stripping, asset injection, share repurchase, equity incentive, bankruptcy restructuring, major business cooperation, introduction of strategic investors and other major matters.
(III) media reports, market rumors and hot concepts
According to the company’s self-examination, the company has not found any media reports or market rumors that may have a great impact on the company’s stock trading price, and has not found any other major events that may have a great impact on the company’s stock price.
(IV) other stock price sensitive information
It is verified that the company’s directors, supervisors, senior managers, controlling shareholders and actual controllers did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that, except for the matters that have been disclosed as required, the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange on the science and Innovation Board (hereinafter referred to as the Listing Rules of the science and Innovation Board) or the planning and intention related to such matters, The board of directors has not been informed of the information that should be disclosed but not disclosed according to the Listing Rules of the science and innovation board and other relevant provisions, which may have a great impact on the trading price of the company’s shares and their derivatives.
4、 Relevant risk tips
(I) profit adjustment risk accumulated by secondary market transactions and continuous rise of the company’s share price
The company’s stock has increased by more than 30% in the last two consecutive trading days, and the continuous rise of the stock price has accumulated more profit adjustment risks. The company specially reminds the majority of investors that the number of circulating shares of the company is 22210796, accounting for 20.82% of the total number of shares after issuance, and the listed circulation is small. On January 14, 2022, the turnover rate of stock trading reached 45.64%, of which natural person investors accounted for a large proportion, which was prone to speculation. On January 15, 2022, the company issued the announcement of Hangzhou Biotest Biotech Co.Ltd(688767) 2021 annual performance pre increase at the same time. The company reminded investors to pay attention to investment risks, avoid following the trend of speculation, make rational decisions and invest prudently
(II) risk of fierce competition in covid-19 product testing market in Europe and Australia
The company obtained the New Coronavirus COVID-19Antigen Rapid Test Cassette (Nasal Swab) CE certification in September 1, 2021, and obtained the New Coronavirus antigen self testing reagent product (COVID-19Antigen Rapid Test Cassette) in October 15, 2021 self testing Australia. There are many similar products or other testing products in the European and Australian markets, and the company’s products will face the risk of fierce market competition.
(III) uncertain risk of future performance growth
Whether the company’s future sales performance can continue to maintain a significant growth trend is uncertain, which is affected by many factors, such as overseas epidemic development and epidemic prevention and control policies, market competition, path selection of international epidemic on technical products, product competitiveness and channel ability of the company, customer recognition and so on, The sales and profit contribution of the above covid-19 products are uncertain. Please pay attention to the investment risk.
(IV) other risks leading to the uncertainty of the company’s operating performance
1. Covid-19 vaccination plan and covid-19 specific drug implementation lead to the risk of uncertain demand. With the increase in the number of global covid-19 vaccinations and the use of covid-19 specific drugs, there may be some uncertainty in the demand for covid-19 testing products.
2. The risk of limited capacity expansion of the company’s products. The production capacity of covid-19 testing reagent products of the company is limited by raw material supply, site, personnel, equipment and production management level. There is a certain upper limit of production capacity, and the business performance of the company is unpredictable. The company specially reminds investors to pay attention to investment risks, cautious valuation, rational decision-making and prudent investment.
The company solemnly reminds investors that Shanghai Securities News, China Securities News, securities times, securities daily and economic reference daily are the designated information disclosure newspapers of the company, and the website of Shanghai Stock Exchange (www.sse. Com. CN) Specify an information disclosure website for the company. All information of the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to investment risks.
5、 Online announcement attachment
Written replies from controlling shareholders and actual controllers
It is hereby announced.
Hangzhou Biotest Biotech Co.Ltd(688767) board of directors January 15, 2022
